Loading...

Donald N Forthal

Title(s)Professor, Medicine
Address1001 Health Sciences Road
Irvine CA 92697-3950
Phone(949) 824-3366
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    The Fc neonatal receptor and antibody-dependent enhancement of dengue virus infection
    NIH R21AI149255Jan 23, 2020 - Dec 31, 2021
    Role: Principal Investigator
    The role of antibody and the Fc neonatal receptor in transmitted/founder strain selection
    NIH R01AI118581Jun 15, 2015 - May 31, 2021
    Role: Principal Investigator
    The impact of antibody and pH on female-to-male SIV infection
    NIH R01AI102715Jul 6, 2012 - Jun 30, 2017
    Role: Principal Investigator
    Broadly Reactive Antibodies Against Chimeric Virus-Host Antigens
    NIH R01AI090656Jun 14, 2010 - May 31, 2014
    Role: Principal Investigator
    Iron Starvation: A novel strategy for HIV and Chlamydia microbicides
    NIH R33AI079775May 1, 2009 - Jul 31, 2016
    Role: Co-Principal Investigator
    Iron Starvation: A novel strategy for HIV and Chlamydia microbicides
    NIH R21AI079775May 1, 2009 - Aug 15, 2011
    Role: Principal Investigator
    Protective immunity against HIV: the role of IgG subclass and glycosylation
    NIH R21AI078477Mar 1, 2008 - Aug 31, 2010
    Role: Principal Investigator
    Fcy Receptor Polymorphisms and Risk of HIV Infection
    NIH R21AI073147Jul 15, 2007 - Jun 30, 2009
    Role: Principal Investigator
    Novel Biological Activities of Anti-Viral Antibody
    NIH R01AI052039Jun 1, 2002 - May 31, 2007
    Role: Principal Investigator
    IMMUNOPROPHYLAXIS--DEFINING PROTECTIVE ANTIBODY FUNCTION
    NIH R03AI044610Jun 1, 1999 - May 31, 2002
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Adaptive immune responses to SARS-CoV-2. Adv Drug Deliv Rev. 2021 Feb 18. Forthal D. PMID: 33610693.
      View in: PubMed   Mentions:    Fields:    
    2. Virus Control in Vaccinated Rhesus Macaques Is Associated with Neutralizing and Capturing Antibodies against the SHIV Challenge Virus but Not with V1V2 Vaccine-Induced Anti-V2 Antibodies Alone. J Immunol. 2021 Feb 03. Hessell AJ, Li L, Malherbe DC, Barnette P, Pandey S, Sutton W, Spencer D, Wang XH, Gach JS, Hunegnaw R, Tuen M, Jiang X, Luo CC, LaBranche CC, Shao Y, Montefiori DC, Forthal DN, Duerr R, Robert-Guroff M, Haigwood NL, Gorny MK. PMID: 33536254.
      View in: PubMed   Mentions:    Fields:    
    3. COVID-19: An unprecedented challenge and an opportunity for change. Adv Drug Deliv Rev. 2021 Jan 29; 171:48-49. Kwon YJ, Forthal D. PMID: 33524417.
      View in: PubMed   Mentions:    Fields:    
    4. Expanded Access Programs, compassionate drug use, and Emergency Use Authorizations during the COVID-19 pandemic. Drug Discov Today. 2020 Nov 27. PMID: 33253920.
      View in: PubMed   Mentions:    Fields:    
    5. Pharmaco-Immunomodulatory Therapy in COVID-19. Drugs. 2020 Sep; 80(13):1267-1292. Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. PMID: 32696108.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCellsPHPublic Health
    6. Authors' Reply to Vrachatis et al. "Pharmaco-Immunomodulatory Therapy I COVID-19". Drugs. 2020 09; 80(14):1501-1503. Rizk JG, Kalantar-Zadeh K, Mehra MR, Lavie CJ, Rizk Y, Forthal DN. PMID: 32880806.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    7. Reopening Schools Safely: The Case for Collaboration, Constructive Disruption of Pre-Coronavirus 2019 Expectations, and Creative Solutions. J Pediatr. 2020 08; 223:183-185. PMID: 32445649.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsPHPublic Health
    8. Impact of Th1 CD4 Follicular Helper T Cell Skewing on Antibody Responses to an HIV-1 Vaccine in Rhesus Macaques. J Virol. 2020 02 28; 94(6). Verma A, Schmidt BA, Elizaldi SR, Nguyen NK, Walter KA, Beck Z, Trinh HV, Dinasarapu AR, Lakshmanappa YS, Rane NN, Matyas GR, Rao M, Shen X, Tomaras GD, LaBranche CC, Reimann KA, Foehl DH, Gach JS, Forthal DN, Kozlowski PA, Amara RR, Iyer SS. PMID: 31827000.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    9. Expression of CD40L by the ALVAC-Simian Immunodeficiency Virus Vector Abrogates T Cell Responses in Macaques. J Virol. 2020 02 28; 94(6). Silva de Castro I, Gordon SN, Liu J, Bissa M, McKinnon K, Trinh HV, Doster MN, Schifanella L, Liyanage NP, Cao J, Cheng O, Foulds K, Roederer M, Koup RA, Shen X, Tomaras GD, Venzon DJ, Forthal DN, Fouts T, Montefiori DC, Tartaglia J, Rao M, Ostrowski M, Franchini G, Vaccari M. PMID: 31896599.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    10. Association of complement C3d receptor 2 genotypes with the acquisition of HIV infection in a trial of recombinant glycoprotein 120 vaccine. AIDS. 2020 01 01; 34(1):25-32. Meza G, Expósito A, Royo JL, Ruiz-García C, Sánchez-Arcas B, Marquez FJ, Gómez-Vidal MA, Omar M, Sinangil F, Higgins K, Forthal D, Real LM, Caruz A. PMID: 31634193.
      View in: PubMed   Mentions:    Fields:    
    11. Correction for Kibler et al., "Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC". J Virol. 2019 Nov 01; 93(21). Kibler KV, Asbach B, Perdiguero B, García-Arriaza J, Yates NL, Parks R, Stanfield-Oakley S, Ferrari G, Montefiori DC, Tomaras GD, Roederer M, Foulds KE, Forthal DN, Seaman MS, Self S, Gottardo R, Phogat S, Tartaglia J, Barnett S, Cristillo AD, Weiss D, Galmin L, Ding S, Heeney JL, Esteban M, Wagner R, Pantaleo G, Jacobs BL. PMID: 31615930.
      View in: PubMed   Mentions: 1     Fields:    
    12. Antibody Responses Elicited by Immunization with BG505 Trimer Immune Complexes. J Virol. 2019 10 15; 93(20). Gach JS, Mara KJV, LaBranche CC, van Gils MJ, McCoy LE, Klasse PJ, Montefiori DC, Sanders RW, Moore JP, Forthal DN. PMID: 31375582.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCellsPHPublic Health
    13. Brucellosis Presenting as Cholecystitis: A Case Report and Literature Review. Open Forum Infect Dis. 2019 Oct; 6(10):ofz334. Speiser L, Hsieh L, Huang SS, Bittencourt C, Forthal D. PMID: 31660329.
      View in: PubMed   Mentions:
    14. Replication-Competent NYVAC-KC Yields Improved Immunogenicity to HIV-1 Antigens in Rhesus Macaques Compared to Nonreplicating NYVAC. J Virol. 2019 02 01; 93(3). Kibler KV, Asbach B, Perdiguero B, García-Arriaza J, Yates NL, Parks R, Stanfield-Oakley S, Ferrari G, Montefiori DC, Tomaras GD, Roederer M, Foulds KE, Forthal DN, Seaman MS, Self S, Gottardo R, Phogat S, Tartaglia J, Barnett S, Cristillo AD, Weiss D, Galmin L, Ding S, Heeney JL, Esteban M, Wagner R, Pantaleo G, Jacobs BL. PMID: 30429340.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    15. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost. J Virol. 2019 02 01; 93(3). Asbach B, Kibler KV, Köstler J, Perdiguero B, Yates NL, Stanfield-Oakley S, Tomaras GD, Kao SF, Foulds KE, Roederer M, Seaman MS, Montefiori DC, Parks R, Ferrari G, Forthal DN, Phogat S, Tartaglia J, Barnett SW, Self SG, Gottardo R, Cristillo AD, Weiss DE, Galmin L, Ding S, Heeney JL, Esteban M, Jacobs BL, Pantaleo G, Wagner R. PMID: 30429343.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    16. Blocking HIV-1 replication: are Fc-Fc? receptor interactions required? J Clin Invest. 2019 01 02; 129(1):53-54. Forthal D, Finzi A. PMID: 30475231.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    17. Antibody-dependent cellular cytotoxicity in HIV infection. AIDS. 2018 11 13; 32(17):2439-2451. Forthal DN, Finzi A. PMID: 30234611.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    18. HIV vaccine candidate activation of hypoxia and the inflammasome in CD14+ monocytes is associated with a decreased risk of SIVmac251 acquisition. Nat Med. 2018 06; 24(6):847-856. Vaccari M, Fourati S, Gordon SN, Brown DR, Bissa M, Schifanella L, Silva de Castro I, Doster MN, Galli V, Omsland M, Fujikawa D, Gorini G, Liyanage NPM, Trinh HV, McKinnon KM, Foulds KE, Keele BF, Roederer M, Koup RA, Shen X, Tomaras GD, Wong MP, Munoz KJ, Gach JS, Forthal DN, Montefiori DC, Venzon DJ, Felber BK, Rosati M, Pavlakis GN, Rao M, Sekaly RP, Franchini G. PMID: 29785023.
      View in: PubMed   Mentions: 17     Fields:    Translation:AnimalsCells
    19. Combination Adenovirus and Protein Vaccines Prevent Infection or Reduce Viral Burden after Heterologous Clade C Simian-Human Immunodeficiency Virus Mucosal Challenge. J Virol. 2018 01 15; 92(2). PMID: 29093095.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    20. Human immunodeficiency virus type-1 (HIV-1) evades antibody-dependent phagocytosis. PLoS Pathog. 2017 12; 13(12):e1006793. Gach JS, Bouzin M, Wong MP, Chromikova V, Gorlani A, Yu KT, Sharma B, Gratton E, Forthal DN. PMID: 29281723.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    21. Diversity of Antiviral IgG Effector Activities Observed in HIV-Infected and Vaccinated Subjects. J Immunol. 2016 12 15; 197(12):4603-4612. PMID: 27913647.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCellsPHPublic Health
    22. Corrigendum: Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med. 2016 10 06; 22(10):1192. PMID: 27711066.
      View in: PubMed   Mentions: 6     Fields:    
    23. Relationship between Vaccine-Induced Antibody Capture of Infectious Virus and Infection Outcomes following Repeated Low-Dose Rectal Challenges with Simian Immunodeficiency Virus SIVmac251. J Virol. 2016 10 01; 90(19):8487-95. PMID: 27440881.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    24. Boosting of ALVAC-SIV Vaccine-Primed Macaques with the CD4-SIVgp120 Fusion Protein Elicits Antibodies to V2 Associated with a Decreased Risk of SIVmac251 Acquisition. J Immunol. 2016 10 01; 197(7):2726-37. PMID: 27591322.
      View in: PubMed   Mentions: 15     Fields:    Translation:AnimalsCells
    25. HIV-1-Specific Antibody Response and Function after DNA Prime and Recombinant Adenovirus 5 Boost HIV Vaccine in HIV-Infected Subjects. PLoS One. 2016; 11(8):e0160341. PMID: 27500639.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCellsCTClinical Trials
    26. Adjuvant-dependent innate and adaptive immune signatures of risk of SIVmac251 acquisition. Nat Med. 2016 07; 22(7):762-70. PMID: 27239761.
      View in: PubMed   Mentions: 68     Fields:    Translation:AnimalsCells
    27. Potential To Streamline Heterologous DNA Prime and NYVAC/Protein Boost HIV Vaccine Regimens in Rhesus Macaques by Employing Improved Antigens. J Virol. 2016 Apr; 90(8):4133-4149. PMID: 26865719.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCellsPHPublic Health
    28. Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations. Mol Immunol. 2016 Feb; 70:94-103. PMID: 26748387.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    29. HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans. EBioMedicine. 2015 Oct; 2(10):1464-77. PMID: 26629541.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCells
    30. Glycan modulation and sulfoengineering of anti-HIV-1 monoclonal antibody PG9 in plants. Proc Natl Acad Sci U S A. 2015 Oct 13; 112(41):12675-80. PMID: 26417081.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansAnimalsCells
    31. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathog. 2015 Aug; 11(8):e1005042. PMID: 26237403.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansAnimalsCells
    32. Association of VH4-59 Antibody Variable Gene Usage with Recognition of an Immunodominant Epitope on the HIV-1 Gag Protein. PLoS One. 2015; 10(7):e0133509. PMID: 26226263.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    33. A High Throughput Protein Microarray Approach to Classify HIV Monoclonal Antibodies and Variant Antigens. PLoS One. 2015; 10(5):e0125581. PMID: 25938510.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    34. Defense-in-depth by mucosally administered anti-HIV dimeric IgA2 and systemic IgG1 mAbs: complete protection of rhesus monkeys from mucosal SHIV challenge. Vaccine. 2015 Apr 21; 33(17):2086-95. PMID: 25769884.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansAnimalsCells
    35. Introduction of germline residues improves the stability of anti-HIV mAb 2G12-IgM. Biochim Biophys Acta. 2015 Oct; 1854(10 Pt A):1536-44. PMID: 25748881.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimalsCells
    36. Multimodality vaccination against clade C SHIV: partial protection against mucosal challenges with a heterologous tier 2 virus. Vaccine. 2014 Nov 12; 32(48):6527-36. PMID: 25245933.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCellsPHPublic Health
    37. Functions of Antibodies. Microbiol Spectr. 2014 Aug 15; 2(4):1-17. PMID: 25215264.
      View in: PubMed   Mentions: 16     Fields:    
    38. Functions of Antibodies. Microbiol Spectr. 2014 Aug; 2(4):AID-0019-2014. PMID: 26104200.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimals
    39. Chemically modified peptides based on the membrane-proximal external region of the HIV-1 envelope induce high-titer, epitope-specific nonneutralizing antibodies in rabbits. Clin Vaccine Immunol. 2014 Aug; 21(8):1086-93. PMID: 24872518.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCells
    40. Enhanced in vitro transcytosis of simian immunodeficiency virus mediated by vaccine-induced antibody predicts transmitted/founder strain number after rectal challenge. J Infect Dis. 2015 Jan 01; 211(1):45-52. PMID: 24850790.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    41. Passive immunization of macaques with polyclonal anti-SHIV IgG against a heterologous tier 2 SHIV: outcome depends on IgG dose. Retrovirology. 2014 Jan 20; 11:8. PMID: 24444350.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    42. HIV-1 specific antibody titers and neutralization among chronically infected patients on long-term suppressive antiretroviral therapy (ART): a cross-sectional study. PLoS One. 2014; 9(1):e85371. PMID: 24454852.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    43. The Neonatal Fc receptor (FcRn) enhances human immunodeficiency virus type 1 (HIV-1) transcytosis across epithelial cells. PLoS Pathog. 2013; 9(11):e1003776. PMID: 24278022.
      View in: PubMed   Mentions: 39     Fields:    Translation:HumansCellsCTClinical Trials
    44. New paradigms for functional HIV-specific nonneutralizing antibodies. Curr Opin HIV AIDS. 2013 Sep; 8(5):393-401. PMID: 23924999.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCells
    45. A human antibody to the CD4 binding site of gp120 capable of highly potent but sporadic cross clade neutralization of primary HIV-1. PLoS One. 2013; 8(8):e72054. PMID: 23991039.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    46. Neutralizing polyclonal IgG present during acute infection prevents rapid disease onset in simian-human immunodeficiency virus SHIVSF162P3-infected infant rhesus macaques. J Virol. 2013 Oct; 87(19):10447-59. PMID: 23885083.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    47. Antibody-dependent enhancement and the risk of HIV infection. Curr HIV Res. 2013 Jul; 11(5):421-6. PMID: 24191936.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    48. Anti-HIV IgA isotypes: differential virion capture and inhibition of transcytosis are linked to prevention of mucosal R5 SHIV transmission. AIDS. 2013 Jun 01; 27(9):F13-20. PMID: 23775002.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansAnimalsCells
    49. Antibody-dependent cell-mediated virus inhibition antibody activity does not correlate with risk of HIV-1 superinfection. . 2013 May 01; 63(1):31-3. PMID: 23344546.
      View in: PubMed   Mentions:
    50. Rapid high-level production of functional HIV broadly neutralizing monoclonal antibodies in transient plant expression systems. PLoS One. 2013; 8(3):e58724. PMID: 23533588.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    51. Protection afforded by an HIV vaccine candidate in macaques depends on the dose of SIVmac251 at challenge exposure. J Virol. 2013 Mar; 87(6):3538-48. PMID: 23325681.
      View in: PubMed   Mentions: 32     Fields:    Translation:AnimalsCells
    52. Association of Fc? receptor IIIa genotype with the rate of HIV infection after gp120 vaccination. Blood. 2012 Oct 04; 120(14):2836-42. PMID: 22915639.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    53. In vitro anti-HIV-1 activity of salicylidene acylhydrazide compounds. Int J Antimicrob Agents. 2012 Oct; 40(4):354-60. PMID: 22819150.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    54. Prolonged tenofovir treatment of macaques infected with K65R reverse transcriptase mutants of SIV results in the development of antiviral immune responses that control virus replication after drug withdrawal. Retrovirology. 2012 Jul 17; 9:57. PMID: 22805180.
      View in: PubMed   Mentions: 11     Fields:    Translation:AnimalsCells
    55. A nonfucosylated variant of the anti-HIV-1 monoclonal antibody b12 has enhanced Fc?RIIIa-mediated antiviral activity in vitro but does not improve protection against mucosal SHIV challenge in macaques. J Virol. 2012 Jun; 86(11):6189-96. Moldt B, Shibata-Koyama M, Rakasz EG, Schultz N, Kanda Y, Dunlop DC, Finstad SL, Jin C, Landucci G, Alpert MD, Dugast AS, Parren PW, Nimmerjahn F, Evans DT, Alter G, Forthal DN, Schmitz JE, Iida S, Poignard P, Watkins DI, Hessell AJ, Burton DR. PMID: 22457527.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimalsCells
    56. Evaluation of heterologous vaginal SHIV SF162p4 infection following vaccination with a polyvalent Clade B virus-like particle vaccine. AIDS Res Hum Retroviruses. 2012 Sep; 28(9):1063-72. PMID: 22214267.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    57. High-level, lasting antiviral immunity induced by a bimodal AIDS vaccine and boosted by live-virus exposure: prevention of viremia. AIDS. 2012 Jan 14; 26(2):149-55. PMID: 21941166.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCells
    58. Vaccine protection against acquisition of neutralization-resistant SIV challenges in rhesus monkeys. Nature. 2012 Jan 04; 482(7383):89-93. PMID: 22217938.
      View in: PubMed   Mentions: 273     Fields:    Translation:AnimalsCells
    59. IgG2 inhibits HIV-1 internalization by monocytes, and IgG subclass binding is affected by gp120 glycosylation. AIDS. 2011 Nov 13; 25(17):2099-104. PMID: 21832933.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCells
    60. Vaccine induced antibodies to the first variable loop of human immunodeficiency virus type 1 gp120, mediate antibody-dependent virus inhibition in macaques. Vaccine. 2011 Dec 09; 30(1):78-94. PMID: 22037204.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    61. Fc-glycosylation influences Fc? receptor binding and cell-mediated anti-HIV activity of monoclonal antibody 2G12. J Immunol. 2010 Dec 01; 185(11):6876-82. Forthal DN, Gach JS, Landucci G, Jez J, Strasser R, Kunert R, Steinkellner H. PMID: 21041724.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansAnimalsCells
    62. Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med. 2010 Oct; 16(10):1117-9. Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delio P, Kuller L, Anderson D, Landucci G, Richardson BA, Burton DR, Forthal DN, Haigwood NL. PMID: 20890292.
      View in: PubMed   Mentions: 81     Fields:    Translation:AnimalsCells
    63. Anti-phospholipid human monoclonal antibodies inhibit CCR5-tropic HIV-1 and induce beta-chemokines. J Exp Med. 2010 Apr 12; 207(4):763-76. Moody MA, Liao HX, Alam SM, Scearce RM, Plonk MK, Kozink DM, Drinker MS, Zhang R, Xia SM, Sutherland LL, Tomaras GD, Giles IP, Kappes JC, Ochsenbauer-Jambor C, Edmonds TG, Soares M, Barbero G, Forthal DN, Landucci G, Chang C, King SW, Kavlie A, Denny TN, Hwang KK, Chen PP, Thorpe PE, Montefiori DC, Haynes BF. PMID: 20368576.
      View in: PubMed   Mentions: 27     Fields:    Translation:HumansCells
    64. Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane-proximal external region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol. 2010 Feb; 84(3):1302-13. Hessell AJ, Rakasz EG, Tehrani DM, Huber M, Weisgrau KL, Landucci G, Forthal DN, Koff WC, Poignard P, Watkins DI, Burton DR. PMID: 19906907.
      View in: PubMed   Mentions: 180     Fields:    Translation:HumansCells
    65. Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS. 2009 Sep; 4(5):388-93. Forthal DN, Moog C. PMID: 20048702.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansAnimalsCells
    66. Protective efficacy of a single immunization of a chimeric adenovirus vector-based vaccine against simian immunodeficiency virus challenge in rhesus monkeys. J Virol. 2009 Sep; 83(18):9584-90. Barouch DH, Liu J, Lynch DM, O'Brien KL, La Porte A, Simmons NL, Riggs AM, Clark S, Abbink P, Montefiori DC, Landucci G, Forthal DN, Self SG, Carville A, Mansfield K, Goudsmit J. PMID: 19553307.
      View in: PubMed   Mentions: 18     Fields:    Translation:AnimalsCellsPHPublic Health
    67. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 2009 May; 5(5):e1000433. Hessell AJ, Rakasz EG, Poignard P, Hangartner L, Landucci G, Forthal DN, Koff WC, Watkins DI, Burton DR. PMID: 19436712.
      View in: PubMed   Mentions: 288     Fields:    Translation:HumansAnimalsCells
    68. Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys. Nature. 2009 Jan 01; 457(7225):87-91. Liu J, O'Brien KL, Lynch DM, Simmons NL, La Porte A, Riggs AM, Abbink P, Coffey RT, Grandpre LE, Seaman MS, Landucci G, Forthal DN, Montefiori DC, Carville A, Mansfield KG, Havenga MJ, Pau MG, Goudsmit J, Barouch DH. PMID: 18997770.
      View in: PubMed   Mentions: 267     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    69. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J Virol. 2008 Dec; 82(24):12449-63. Tomaras GD, Yates NL, Liu P, Qin L, Fouda GG, Chavez LL, Decamp AC, Parks RJ, Ashley VC, Lucas JT, Cohen M, Eron J, Hicks CB, Liao HX, Self SG, Landucci G, Forthal DN, Weinhold KJ, Keele BF, Hahn BH, Greenberg ML, Morris L, Karim SS, Blattner WA, Montefiori DC, Shaw GM, Perelson AS, Haynes BF. PMID: 18842730.
      View in: PubMed   Mentions: 302     Fields:    Translation:HumansCells
    70. Heavily glycosylated, highly fit SIVMne variants continue to diversify and undergo selection after transmission to a new host and they elicit early antibody dependent cellular responses but delayed neutralizing antibody responses. Virol J. 2008 Aug 04; 5:90. Eastman D, Piantadosi A, Wu X, Forthal DN, Landucci G, Kimata JT, Overbaugh J. PMID: 18680596.
      View in: PubMed   Mentions: 4     Fields:    Translation:AnimalsCells
    71. FcgammaRIIa genotype predicts progression of HIV infection. J Immunol. 2007 Dec 01; 179(11):7916-23. Forthal DN, Landucci G, Bream J, Jacobson LP, Phan TB, Montoya B. PMID: 18025239.
      View in: PubMed   Mentions: 65     Fields:    Translation:HumansCells
    72. Fc receptor but not complement binding is important in antibody protection against HIV. Nature. 2007 Sep 06; 449(7158):101-4. Hessell AJ, Hangartner L, Hunter M, Havenith CE, Beurskens FJ, Bakker JM, Lanigan CM, Landucci G, Forthal DN, Parren PW, Marx PA, Burton DR. PMID: 17805298.
      View in: PubMed   Mentions: 438     Fields:    Translation:HumansAnimalsCells
    73. Recombinant gp120 vaccine-induced antibodies inhibit clinical strains of HIV-1 in the presence of Fc receptor-bearing effector cells and correlate inversely with HIV infection rate. J Immunol. 2007 May 15; 178(10):6596-603. Forthal DN, Gilbert PB, Landucci G, Phan T. PMID: 17475891.
      View in: PubMed   Mentions: 108     Fields:    Translation:HumansCells
    74. Antiviral antibodies are necessary for control of simian immunodeficiency virus replication. J Virol. 2007 May; 81(10):5024-35. Miller CJ, Genescà M, Abel K, Montefiori D, Forthal D, Bost K, Li J, Favre D, McCune JM. PMID: 17329327.
      View in: PubMed   Mentions: 48     Fields:    Translation:AnimalsCells
    75. Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol. 2006 Sep 15; 177(6):4028-36. Florese RH, Van Rompay KK, Aldrich K, Forthal DN, Landucci G, Mahalanabis M, Haigwood N, Venzon D, Kalyanaraman VS, Marthas ML, Robert-Guroff M. PMID: 16951366.
      View in: PubMed   Mentions: 40     Fields:    Translation:AnimalsCells
    76. Rhesus macaque polyclonal and monoclonal antibodies inhibit simian immunodeficiency virus in the presence of human or autologous rhesus effector cells. J Virol. 2006 Sep; 80(18):9217-25. Forthal DN, Landucci G, Cole KS, Marthas M, Becerra JC, Van Rompay K. PMID: 16940533.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansAnimalsCells
    77. Role of CD8+ cells in controlling replication of nonpathogenic Simian Immunodeficiency Virus SIVmac1A11. Virol J. 2006 Apr 03; 3:22. Van Rompay KK, Blackwood EJ, Landucci G, Forthal D, Marthas ML. PMID: 16584561.
      View in: PubMed   Mentions: 5     Fields:    Translation:AnimalsCells
    78. A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575. AIDS. 2005 Feb 18; 19(3):295-302. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Tilles JG, Forthal DN, Leedom J, Leibowitz M, McCutchan JA, Richman DD. PMID: 15718840.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCellsCTClinical Trials
    79. Interactions between natural killer cells and antibody Fc result in enhanced antibody neutralization of human immunodeficiency virus type 1. J Virol. 2005 Feb; 79(4):2042-9. Forthal DN, Landucci G, Phan TB, Becerra J. PMID: 15681406.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    80. Placebo-controlled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis. 2005 Mar 01; 191(5):654-65. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, Para MF. PMID: 15688278.
      View in: PubMed   Mentions: 400     Fields:    Translation:HumansCellsCTClinical Trials
    81. The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients. Antivir Ther. 2004 Oct; 9(5):753-61. Yasuda JM, Miller C, Currier JS, Forthal DN, Kemper CA, Beall GN, Tilles JG, Capparelli EV, McCutchan JA, Haubrich RH. PMID: 15535413.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    82. CD8+ T-cell mediated tumor protection by Pseudomonas exotoxin fused to ovalbumin in C57BL/6 mice. Surgery. 2003 Apr; 133(4):404-10. Becerra JC, Arthur JF, Landucci GR, Forthal DN, Theuer CP. PMID: 12717358.
      View in: PubMed   Mentions: 2     Fields:    Translation:AnimalsCells
    83. The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis. AIDS. 2002 Oct 18; 16(15):F33-40. Haubrich RH, Kemper CA, Hellmann NS, Keiser PH, Witt MD, Forthal DN, Leedom J, Leibowitz M, Whitcomb JM, Richman D, McCutchan JA. PMID: 12370520.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCellsCTClinical Trials
    84. A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy. Clin Infect Dis. 2001 Oct 01; 33(7):1060-8. Haubrich RH, Currier JS, Forthal DN, Beall G, Kemper CA, Johnson D, Dubé MP, Hwang J, Leedom JM, Tilles J, McCutchan JA. PMID: 11528581.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    85. Antibody from patients with acute human immunodeficiency virus (HIV) infection inhibits primary strains of HIV type 1 in the presence of natural-killer effector cells. J Virol. 2001 Aug; 75(15):6953-61. Forthal DN, Landucci G, Daar ES. PMID: 11435575.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansCells
    86. Osteoclasts formed by measles virus-infected osteoclast precursors from hCD46 transgenic mice express characteristics of pagetic osteoclasts. Endocrinology. 2001 Jul; 142(7):2898-905. Reddy SV, Kurihara N, Menaa C, Landucci G, Forthal D, Koop BA, Windle JJ, Roodman GD. PMID: 11416009.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansAnimalsCells
    87. Relationship between antibody-dependent cellular cytotoxicity, plasma HIV type 1 RNA, and CD4+ lymphocyte count. AIDS Res Hum Retroviruses. 2001 Apr 10; 17(6):553-61. Forthal DN, Landucci G, Keenan B. PMID: 11350669.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCells
    88. Sequencing of protease inhibitor therapy: insights from an analysis of HIV phenotypic resistance in patients failing protease inhibitors. AIDS. 2001 Mar 30; 15(5):609-15. Kemper CA, Witt MD, Keiser PH, Dubé MP, Forthal DN, Leibowitz M, Smith DS, Rigby A, Hellmann NS, Lie YS, Leedom J, Richman D, McCutchan JA, Haubrich R. PMID: 11316998.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    89. Antibody inhibition of cytomegalovirus: the role of natural killer and macrophage effector cells. Transpl Infect Dis. 2001; 3 Suppl 2:31-4. Forthal DN, Phan T, Landucci G. PMID: 11926747.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    90. Clinical isolates of measles virus use CD46 as a cellular receptor. J Virol. 2000 May; 74(9):3967-74. Manchester M, Eto DS, Valsamakis A, Liton PB, Fernandez-Muñoz R, Rota PA, Bellini WJ, Forthal DN, Oldstone MB. PMID: 10756008.
      View in: PubMed   Mentions: 47     Fields:    Translation:AnimalsCells
    91. Sex-associated differences in the antibody-dependent cellular cytotoxicity antibody response to measles vaccines. Clin Diagn Lab Immunol. 2000 Jan; 7(1):111-3. Atabani S, Landucci G, Steward MW, Whittle H, Tilles JG, Forthal DN. PMID: 10618288.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    92. Cytotoxic T lymphocyte precursors in persons with repeated exposure to human immunodeficiency virus. J Infect Dis. 1999 Oct; 180(4):1406-7. Forthal DN. PMID: 10479184.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    93. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis. 1999 Oct; 180(4):1338-41. Forthal DN, Landucci G, Haubrich R, Keenan B, Kuppermann BD, Tilles JG, Kaplan J. PMID: 10479168.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansCells
    94. Efficacy of azithromycin in prevention of Pneumocystis carinii pneumonia: a randomised trial. California Collaborative Treatment Group. Lancet. 1999 Sep 11; 354(9182):891-5. Dunne MW, Bozzette S, McCutchan JA, Dubé MP, Sattler FR, Forthal D, Kemper CA, Havlir D. PMID: 10489947.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCellsCTClinical Trials
    95. The value of patient-reported adherence to antiretroviral therapy in predicting virologic and immunologic response. California Collaborative Treatment Group. AIDS. 1999 Jun 18; 13(9):1099-107. Haubrich RH, Little SJ, Currier JS, Forthal DN, Kemper CA, Beall GN, Johnson D, Dubé MP, Hwang JY, McCutchan JA. PMID: 10397541.
      View in: PubMed   Mentions: 111     Fields:    Translation:HumansCellsCTClinical Trials
    96. Prophylaxis with weekly versus daily fluconazole for fungal infections in patients with AIDS. Clin Infect Dis. 1998 Dec; 27(6):1369-75. Havlir DV, Dubé MP, McCutchan JA, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Kumar PN, White AC, Witt MD, Nightingale SD, Sepkowitz KA, MacGregor RR, Cheeseman SH, Torriani FJ, Zelasky MT, Sattler FR, Bozzette SA. PMID: 9868644.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    97. In vitro reduction of virus infectivity by antibody-dependent cell-mediated immunity. J Immunol Methods. 1998 Nov 01; 220(1-2):129-38. Forthal DN, Landucci G. PMID: 9839934.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    98. Human immunodeficiency virus replication in AIDS patients with Mycobacterium avium complex bacteremia: a case control study. California Collaborative Treatment Group. J Infect Dis. 1998 Mar; 177(3):595-9. Havlir DV, Haubrich R, Hwang J, Dunne MW, Currier J, Forthal D, Torriani F, Richman DD, McCutchan JA. PMID: 9498437.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    99. Lymphokine-activated cytotoxicity in peripheral blood mononuclear cells of severely immunocompromised HIV-infected patients. Scand J Immunol. 1997 Jan; 45(1):91-5. Forthal DN, Landucci G, Robinson WE. PMID: 9010505.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    100. Predominance of detrimental humoral immune responses to HIV-1 in AIDS patients with CD4 lymphocyte counts less than 400/mm3. Scand J Immunol. 1997 Jan; 45(1):103-11. McDougall B, Nymark MH, Landucci G, Forthal D, Robinson WE. PMID: 9010507.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    101. Prophylaxis against disseminated Mycobacterium avium complex with weekly azithromycin, daily rifabutin, or both. California Collaborative Treatment Group. N Engl J Med. 1996 Aug 08; 335(6):392-8. Havlir DV, Dubé MP, Sattler FR, Forthal DN, Kemper CA, Dunne MW, Parenti DM, Lavelle JP, White AC, Witt MD, Bozzette SA, McCutchan JA. PMID: 8676932.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCellsCTClinical Trials
    102. Age, sex, and household exposure are associated with the acute measles-specific antibody-dependent cellular cytotoxicity antibody response. J Infect Dis. 1995 Dec; 172(6):1587-91. Forthal DN, Landucci G, Habis A, Laxer M, Javato-Laxer M, Tilles JG, Janoff EN. PMID: 7594722.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    103. Functional activities of 20 human immunodeficiency virus type 1 (HIV-1)-specific human monoclonal antibodies. AIDS Res Hum Retroviruses. 1995 Sep; 11(9):1095-9. Forthal DN, Landucci G, Gorny MK, Zolla-Pazner S, Robinson WE. PMID: 8554906.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    104. The tolerance for zidovudine plus thrice weekly or daily trimethoprim-sulfamethoxazole with and without leucovorin for primary prophylaxis in advanced HIV disease. California Collaborative Treatment Group. Am J Med. 1995 Feb; 98(2):177-82. Bozzette SA, Forthal D, Sattler FR, Kemper C, Richman DD, Tilles JG, Leedom J, McCutchan JA. PMID: 7847434.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    105. Fluconazole combined with flucytosine for treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1994 Oct; 19(4):741-5. Larsen RA, Bozzette SA, Jones BE, Haghighat D, Leal MA, Forthal D, Bauer M, Tilles JG, McCutchan JA, Leedom JM. PMID: 7803641.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansAnimalsCTClinical Trials
    106. Comparison of the ProSpecT and Color Vue enzyme-linked immunoassays for the detection of Cryptosporidium in stool specimens. Diagn Microbiol Infect Dis. 1994 Aug; 19(4):221-5. Aarnaes SL, Blanding J, Speier S, Forthal D, de la Maza LM, Peterson EM. PMID: 7851085.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansAnimals
    107. Measles virus-specific functional antibody responses and viremia during acute measles. J Infect Dis. 1994 Jun; 169(6):1377-80. Forthal DN, Landucci G, Habis A, Zartarian M, Katz J, Tilles JG. PMID: 8195621.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    108. Comparison of measles virus-specific antibodies with antibody-dependent cellular cytotoxicity and neutralizing functions. J Infect Dis. 1993 Oct; 168(4):1020-3. Forthal DN, Landucci G, Katz J, Tilles JG. PMID: 8376813.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    109. Comparison of different methods and cell lines for isolating measles virus. J Clin Microbiol. 1993 Mar; 31(3):695-7. Forthal DN, Blanding J, Aarnaes S, Peterson EM, de la Maza LM, Tilles JG. PMID: 8458965.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    110. Degree and length of viremia in adults with measles. J Infect Dis. 1992 Aug; 166(2):421-4. Forthal DN, Aarnaes S, Blanding J, de la Maza L, Tilles JG. PMID: 1634814.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    111. The prevalence of infection with human immunodeficiency virus over a 10-year period in rural Zaire. N Engl J Med. 1988 Feb 04; 318(5):276-9. Nzilambi N, De Cock KM, Forthal DN, Francis H, Ryder RW, Malebe I, Getchell J, Laga M, Piot P, McCormick JB. PMID: 3336420.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    112. Human immunodeficiency virus isolated from a serum sample collected in 1976 in Central Africa. J Infect Dis. 1987 Nov; 156(5):833-7. Getchell JP, Hicks DR, Svinivasan A, Heath JL, York DA, Malonga M, Forthal DN, Mann JM, McCormick JB. PMID: 3309075.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells